TSTickerStarGet alerts

EYPT 10-Q filed 2026-11-12 | Key takeaways

EYPT filed its 10-Q; the most relevant disclosure change is added Subsequent events - strategic prioritization: On October 17, 2026, following review of LUCIA wet AMD trial results, the Board approved a strategic prioritization plan to conclude pivotal Phase 3 wet AMD trials early and reduce workforce by approximately 53%, with estimated aggregate charges of $9.0 millio.

Share this story

Key takeaways

  • Revenue declined 22% to $756K in Q3 2026 from $966K in Q3 2025, driven by lower license and collaboration revenue

  • Net loss widened 60% to $95.6M in Q3 2026 from $59.7M in Q3 2025, primarily due to increased R&D expenses for DURAVYU Phase 3 trials

  • R&D expenses increased 71% to $81.7M in Q3 2026 from $47.8M in Q3 2025, reflecting ongoing wet AMD and DME clinical trials

  • Cash position declined to $118.2M at September 30, 2026 from $328.7M at December 31, 2025, with runway expected into late Q3 2027

  • LUCIA and LUGANO wet AMD Phase 3 trials did not meet primary endpoint of non-inferiority versus aflibercept

  • Strategic prioritization plan announced October 17, 2026 includes concluding wet AMD trials early and 53% workforce reduction

  • DME Phase 3 trials (COMO and CAPRI) fully enrolled with over 550 patients; data readout expected early Q4 2027

Key metrics

Total revenues - Q3Q3 2026
$756K-22%
Total revenues - Nine monthsNine months 2026
$1.96M-94%
Net loss - Q3Q3 2026
$95.6M60%
Net loss - Nine monthsNine months 2026
$274.9M67%
Net loss per share - Q3Q3 2026
-$1.0726%
Net loss per share - Nine monthsNine months 2026
-$3.1534%
Cash and cash equivalentsSeptember 30, 2026
$83.2M
Marketable securitiesSeptember 30, 2026
$35.0M

Disclosure changes

  • Subsequent events - strategic prioritization

    On October 17, 2026, following review of LUCIA wet AMD trial results, the Board approved a strategic prioritization plan to conclude pivotal Phase 3 wet AMD trials early and reduce workforce by approximately 53%, with estimated aggregate charges of $9.0 million for employee separation benefits.

    Major strategic shift following clinical trial failure; significant workforce reduction and cost restructuring
  • Liquidity and going concern

    The company had cash, cash equivalents, and investments of $118.2M at September 30, 2026. Based on current operating plans and excluding future external financing, the company will not have sufficient cash to fund operations beyond one year from issuance of financial statements, raising substantial doubt about ability to continue as a going concern.

    Going concern doubt exists; company needs additional funding to continue operations
  • DOJ settlement

    On July 17, 2026, the company entered into a settlement agreement with DOJ to pay $4,678,981.86 plus interest for settlement of False Claims Act and Anti-Kickback Statute investigation related to DEXYCU sales and marketing practices. The settlement was paid in full on July 31, 2026. A Corporate Integrity Agreement with HHS requires compliance programs for five years.

    Legal settlement resolved; ongoing compliance obligations
  • Clinical trial results - wet AMD

    LUGANO and LUCIA pivotal Phase 3 trials for DURAVYU in wet AMD did not meet primary endpoint of non-inferiority in mean change in BCVA versus aflibercept control, announced August 17, 2026 and October 19, 2026 respectively.

    Key clinical trial failure for lead product candidate in primary indication
  • DME clinical trials

    Pivotal Phase 3 clinical trials (COMO and CAPRI) in diabetic macular edema are fully enrolled with over 550 patients. First patients dosed February 2026; enrollment completed July 2026. Initial data readout expected early Q4 2027.

    Company's focus shifting to DME indication following wet AMD failure
  • ATM facility activity

    During nine months ended September 30, 2026, the company sold 4,478,989 shares under ATM facility at weighted average price of $10.30 for gross proceeds of $46.1M. Subsequent to September 30, 2026, sold 22,992,900 shares at weighted average price of $0.44 for gross proceeds of $10.1M.

    Significant equity dilution; recent share sales at substantially lower prices

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow EYPT in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert